Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Ryanair posts 16% drop in full-year profits

(Sharecast News) - Budget airline Ryanair reported a 16% decline in full-year profit on Monday as average fares fell. In the year to the end of March, profit after tax dropped to €1.61bn from €1.92bn the year before, as average fares declined 7%.

Passenger numbers rose 9% to a record 200.2m despite Boeing delivery delays and revenue ticked up 4% to €13.44bn. The load factor - which gauges how full the planes are - was steady at 94%.

Operating costs were in line with Ryanair's expectations, rising 9% to €12.39bn as fuel hedge savings offset higher staff and other costs due in part to repeated Boeing delivery delays.

Ryanair said it expects FY26 traffic to grow by just 3% to 206m passengers due to constrained/delayed Boeing deliveries.

Chief executive officer Michael O'Leary said: "While we cautiously expect to recover most, but not all of last year's 7% fare decline, which should lead to reasonable net profit growth in FY26, it is far too early to provide any meaningful guidance.

"The final FY26 outcome remains heavily exposed to adverse external developments, incl. the risk of tariff wars, macro-economic shocks, conflict escalation in Ukraine and the Middle East and European ATC mismanagement/ short staffing."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.